KOD drugs meet primary endpoints in DAYBREAK trial
Zenkuda and tabirafusp-ted met primary endpoints in the pivotal DAYBREAK trial in wet age-related macular degeneration.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.